Strand Therapeutics

Strand Therapeutics is an emerging biopharmaceutical company applying synthetic biology to RNA therapeutics and has developed the first platform for creating programmable, long-acting mRNA drugs capable of delivering precise, multifunctional, potentially curative treatments in a single dose. Strand’s technology could have broad applicability across a range of diseases. The company will initially focus on developing mRNA therapies that work through multiple immune-mediated mechanisms to provide potential cancer treatments. In solid tumors, Strand’s mRNA approach has the potential to significantly improve response rates to checkpoint inhibitor therapy. In hematologic malignancies, Strand’s early work holds the potential to revolutionize CAR-T therapy.